UK biotech Nucleome Therapeutics has been thrust into the spotlight thanks to a £37.5 million ($40 million) first-round financing that will be used to explore so-called 'dark' regions of th
BeiGene's BTK inhibitor Brukinsa (zanubrutinib) has become the first drug in the class to be recommended for routine NHS use in England and Wales to treat Waldenström macroglobulinaemia (WM
NICE has said it is unable to recommend NHS use of AstraZeneca's Lynparza for some patients with prostate cancer, after failing to reach an agreement on price with the drugmaker.
New UK Prime Minister Liz Truss needs to take immediate action to prevent the NHS spiralling out of control this winter, according to groups representing healthcare workers.
The UK Competition and Markets Authority (CMA) is seeking to disqualify Peter Butterfield, currently chief executive of Alliance Pharma, from serving as a company director.
UK biotech Mereo BioPharma is attempting to face down a revolt by Rubric Capital Management – its largest shareholder holding around 14% of the company – which is agitating for changes to i